Usana Health Sciences (USNA) EBIAT (2016 - 2026)
Usana Health Sciences (USNA) has disclosed EBIAT for 16 consecutive years, with -$6.5 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 161.49% to -$6.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.0 million, a 68.68% decrease, with the full-year FY2024 number at $42.1 million, down 34.06% from a year prior.
- EBIAT was -$6.5 million for Q3 2025 at Usana Health Sciences, down from $9.8 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $40.4 million in Q4 2021 to a low of -$26.8 million in Q4 2022.
- A 5-year average of $15.2 million and a median of $16.5 million in 2024 define the central range for EBIAT.
- Peak YoY movement for EBIAT: plummeted 185.27% in 2022, then soared 162.48% in 2023.
- Usana Health Sciences' EBIAT stood at $40.4 million in 2021, then tumbled by 166.51% to -$26.8 million in 2022, then skyrocketed by 162.48% to $16.8 million in 2023, then plummeted by 73.26% to $4.5 million in 2024, then tumbled by 245.45% to -$6.5 million in 2025.
- Per Business Quant, the three most recent readings for USNA's EBIAT are -$6.5 million (Q3 2025), $9.8 million (Q2 2025), and $9.3 million (Q1 2025).